{"id":"levetiracetam-keppra","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Behavioral/mood changes (irritability, aggression)"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL1286","moleculeType":"Small molecule","molecularWeight":"170.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding mechanism is distinct from other antiepileptic drugs and appears to stabilize neuronal membranes and reduce seizure propagation. The exact downstream effects of SV2A binding that lead to anticonvulsant activity are not fully elucidated but likely involve modulation of calcium-dependent neurotransmitter release.","oneSentence":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:51.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Myoclonic seizures in patients with juvenile myoclonic epilepsy (adjunctive therapy)"},{"name":"Primary generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT07490769","phase":"PHASE3","title":"Levetiracetam Three Times Daily in Epilepsy","status":"RECRUITING","sponsor":"Waad Alkathiri","startDate":"2025-10-01","conditions":"Epilepsy","enrollment":120},{"nctId":"NCT07130786","phase":"PHASE2","title":"Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases","status":"RECRUITING","sponsor":"Ayal A. Aizer, MD","startDate":"2025-12-23","conditions":"Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","enrollment":150},{"nctId":"NCT06907173","phase":"PHASE3","title":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2026-02","conditions":"Status Epilepticus","enrollment":770},{"nctId":"NCT07477431","phase":"PHASE2","title":"Levetiracetam for Persons at Risk for Alzheimer's Disease","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10-23","conditions":"Hippocampal Hyperactivation, Prodromal Alzheimer Disease","enrollment":40},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT07271966","phase":"NA","title":"B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-30","conditions":"Brain Tumor Related Epilepsy (BTRE)","enrollment":50},{"nctId":"NCT07422233","phase":"PHASE4","title":"Evaluation of Levetiracetam's Effectiveness and Tolerability for Treating Epilepsy in Older Adults","status":"COMPLETED","sponsor":"Nasim Tabrizi","startDate":"2023-09-13","conditions":"Epilepsy, Elderly","enrollment":137},{"nctId":"NCT06442748","phase":"PHASE3","title":"Short Versus Long-term Levetiracetam in Brain Tumors","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-07-04","conditions":"Seizures, Brain Tumors, Antiepileptics","enrollment":604},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07401433","phase":"NA","title":"Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.","status":"COMPLETED","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2024-04-08","conditions":"Neonatal Seizures","enrollment":260},{"nctId":"NCT07393022","phase":"PHASE1","title":"Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2025-12-17","conditions":"Pharmacokinetic Analysis, Bioequivalence, Health Adult Subjects","enrollment":20},{"nctId":"NCT06866691","phase":"PHASE4","title":"Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04-18","conditions":"Traumatic Brain Injury","enrollment":600},{"nctId":"NCT01150331","phase":"PHASE3","title":"Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-07","conditions":"Status; Epilepticus, Tonic-clonic","enrollment":203},{"nctId":"NCT07336992","phase":"PHASE3","title":"Efficacy of Prophylactic Levetiracetam for Improving Functional Outcome in the Acute Phase of Intracerebral Haemorrhage: a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-02","conditions":"Spontaneous Intracerebral Hemorrhage","enrollment":580},{"nctId":"NCT07234695","phase":"PHASE3","title":"LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2025-12-22","conditions":"Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21)","enrollment":120},{"nctId":"NCT07315048","phase":"NA","title":"Nursing Risk Management in Emergency SAH Surgery Using Healthcare Failure Mode and Effect Analysis(HFMEA)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-03-01","conditions":"Spontaneous Subarachnoid Hemorrhage","enrollment":156},{"nctId":"NCT02229123","phase":"PHASE2","title":"Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2018-02-27","conditions":"Neonatal Seizures","enrollment":18},{"nctId":"NCT07284498","phase":"PHASE4","title":"Treatment of Seizures in Neonate With HIE","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-01","conditions":"Neonatal Seizures, HIE - Hypoxic - Ischemic Encephalopathy","enrollment":66},{"nctId":"NCT03196466","phase":"","title":"Population Pharmacokinetics of Antiepileptic in Pediatrics","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-19","conditions":"Epilepsy","enrollment":753},{"nctId":"NCT07239115","phase":"PHASE3","title":"Levetiracetam for Seizure Prevention After Brain Tumor Surgery","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-01","conditions":"Postoperative Seizures After Brain Tumor Surgery","enrollment":558},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT04833907","phase":"PHASE1, PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":"Canavan Disease","enrollment":24},{"nctId":"NCT06081283","phase":"PHASE4","title":"Antiseizure Medication in Seizure Networks at Early Acute Brain Injury","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-11-20","conditions":"Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia","enrollment":5},{"nctId":"NCT05610085","phase":"PHASE2","title":"A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-03-24","conditions":"Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy","enrollment":133},{"nctId":"NCT04317807","phase":"PHASE2","title":"R33: Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-27","conditions":"Early Psychosis","enrollment":65},{"nctId":"NCT07220902","phase":"PHASE3","title":"Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure","status":"NOT_YET_RECRUITING","sponsor":"Nebraska Methodist Health System","startDate":"2026-01-01","conditions":"Severe Preeclampsia, Eclampsia Preeclampsia","enrollment":1240},{"nctId":"NCT05824728","phase":"PHASE2","title":"Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-28","conditions":"Parkinson Disease Psychosis","enrollment":30},{"nctId":"NCT02631759","phase":"PHASE3","title":"Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Acute intraCerebral Haemorrhage","enrollment":50},{"nctId":"NCT07163572","phase":"NA","title":"Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-16","conditions":"Status Epilepticus","enrollment":152},{"nctId":"NCT07163585","phase":"NA","title":"Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2024-08-01","conditions":"Epilepsy","enrollment":102},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":"Brain Tumors, Epilepsy, Migraine","enrollment":3300},{"nctId":"NCT07072624","phase":"PHASE4","title":"Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Jodhpur","startDate":"2025-07-23","conditions":"Seizures, Traumatic Brain Injuries, Traumatic Brain Injury (TBI) Patients","enrollment":1260},{"nctId":"NCT07098728","phase":"NA","title":"Levetiracetam Versus Phenobarbital in Benzodiazepines Unresponsive Paediatric Prolonged Seizures","status":"RECRUITING","sponsor":"Ministry of Health and Sports, Myanmar","startDate":"2025-07-22","conditions":"Seizure","enrollment":180},{"nctId":"NCT05756621","phase":"","title":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2022-01-15","conditions":"Status Epilepticus, Cardiac Arrest","enrollment":80},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT01666080","phase":"NA","title":"Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-08","conditions":"Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies","enrollment":30},{"nctId":"NCT03034356","phase":"PHASE1, PHASE2","title":"Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-09-01","conditions":"Schizophrenia","enrollment":67},{"nctId":"NCT06982287","phase":"","title":"A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)","status":"NOT_YET_RECRUITING","sponsor":"Yong Fang","startDate":"2025-08-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":100},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT07052136","phase":"NA","title":"Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2024-11-01","conditions":"Status Epilepticus","enrollment":138},{"nctId":"NCT04836559","phase":"PHASE2","title":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-18","conditions":"Focal Onset Seizures","enrollment":110},{"nctId":"NCT07046611","phase":"PHASE2, PHASE3","title":"Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-07-02","conditions":"Generalized Convulsive Status Epilepticus","enrollment":124},{"nctId":"NCT05986721","phase":"PHASE2","title":"Clinical Trial of AGB101 for Mild Cognitive Impairment","status":"WITHDRAWN","sponsor":"AgeneBio","startDate":"2024-12-03","conditions":"Mild Cognitive Impairment, Prodromal Alzheimer's Disease","enrollment":""},{"nctId":"NCT06773364","phase":"PHASE3","title":"Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-04-30","conditions":"Suspected Stroke","enrollment":2423},{"nctId":"NCT06549426","phase":"NA","title":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","status":"RECRUITING","sponsor":"University of Twente","startDate":"2025-04-10","conditions":"Coma, Electrographic Status Epilepticus","enrollment":150},{"nctId":"NCT02201251","phase":"PHASE3","title":"A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-06","conditions":"Epilepsy","enrollment":63},{"nctId":"NCT06919926","phase":"PHASE2","title":"Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-04-17","conditions":"Hippocampal Overactivity, Dementia","enrollment":60},{"nctId":"NCT02647437","phase":"NA","title":"Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-06","conditions":"Schizophrenia","enrollment":18},{"nctId":"NCT06750458","phase":"PHASE3","title":"Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-08-20","conditions":"Glioma, Dapagliflozin (Forxiga), Dexamethasone","enrollment":75},{"nctId":"NCT05450978","phase":"","title":"Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2022-07-20","conditions":"Epilepsy, Pregnancy Related","enrollment":60},{"nctId":"NCT01228747","phase":"PHASE3","title":"A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2010-10","conditions":"Epilepsy, Generalized Tonic-Clonic Seizures","enrollment":361},{"nctId":"NCT06851078","phase":"PHASE3","title":"Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-15","conditions":"Septic Shock","enrollment":280},{"nctId":"NCT03048084","phase":"PHASE4","title":"Seizure Treatment in Glioma","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-02-01","conditions":"Glioma","enrollment":120},{"nctId":"NCT06224530","phase":"NA","title":"Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk","status":"RECRUITING","sponsor":"King's College London","startDate":"2024-07-19","conditions":"Psychosis","enrollment":69},{"nctId":"NCT05263674","phase":"PHASE3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Non-Convulsive Status Epilepticus","enrollment":140},{"nctId":"NCT03875638","phase":"PHASE2","title":"Treating Hyperexcitability in AD With Levetiracetam","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2019-08-22","conditions":"Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type","enrollment":85},{"nctId":"NCT05722951","phase":"PHASE3","title":"Metformin Efficacy and Safety in Epileptic Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-18","conditions":"Epilepsy","enrollment":60},{"nctId":"NCT01801072","phase":"PHASE4","title":"Seizure Prophylaxis in Aneurysm Repair","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2013-02","conditions":"Intracranial Aneurysms, Seizure","enrollment":82},{"nctId":"NCT05897658","phase":"PHASE3","title":"Levetiracetam Prophylaxis in Brain Tumor Resection Pilot","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-03","conditions":"Seizures, Brain Tumor","enrollment":70},{"nctId":"NCT03071913","phase":"","title":"Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-09-20","conditions":"Central Nervous System Neoplasm, Localized Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain","enrollment":54},{"nctId":"NCT04643327","phase":"PHASE2","title":"Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2021-02-09","conditions":"Parkinson Disease, Mild Cognitive Impairment, Memory Impairment","enrollment":28},{"nctId":"NCT00859430","phase":"PHASE1","title":"Levetiracetam 1000 mg Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2007-01","conditions":"Healthy","enrollment":22},{"nctId":"NCT00859521","phase":"PHASE1","title":"Levetiracetam 1000 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2007-01","conditions":"Healthy","enrollment":30},{"nctId":"NCT04497142","phase":"PHASE1, PHASE2","title":"Effect of Perampanel on Peritumoral Hyperexcitability in HGG","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-05","conditions":"Glioma, Malignant, Surgery, Seizures","enrollment":12},{"nctId":"NCT03340064","phase":"PHASE3","title":"A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2017-11-30","conditions":"Partial Seizures","enrollment":38},{"nctId":"NCT06498362","phase":"","title":"The \"New\" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-11-16","conditions":"Epilepsy in Children","enrollment":151},{"nctId":"NCT06491303","phase":"","title":"Effects of Levetiracetam Monotherapy on Various Hematological Parameters in Adult Patients Suffering of Epilepsy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-11-01","conditions":"Neutropenia, Thrombocytopenia, Aplastic Anemia","enrollment":45},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT06403150","phase":"PHASE4","title":"The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus","status":"ENROLLING_BY_INVITATION","sponsor":"Dhaka Medical College","startDate":"2023-05-15","conditions":"Status Epilepticus","enrollment":62},{"nctId":"NCT06393309","phase":"","title":"Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2022-09-03","conditions":"Treatment of Idiopathic Generalized Epilepsy","enrollment":169},{"nctId":"NCT03489044","phase":"PHASE2","title":"An Investigation of Levetiracetam in Alzheimer's Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-10-28","conditions":"Alzheimer Disease, Epilepsy","enrollment":8},{"nctId":"NCT05450822","phase":"","title":"Precision Medicine in the Treatment of Epilepsy","status":"RECRUITING","sponsor":"Gitte Moos Knudsen","startDate":"2022-02-18","conditions":"Epilepsy","enrollment":550},{"nctId":"NCT05543122","phase":"","title":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-03-09","conditions":"Breast Feeding","enrollment":39},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT02421068","phase":"","title":"Population PK/PD of Off Label Drugs in Premature Neonates","status":"COMPLETED","sponsor":"Sinno H.P. Simons","startDate":"2014-08","conditions":"Premature Birth","enrollment":246},{"nctId":"NCT02866877","phase":"","title":"Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-01","conditions":"Subarachnoid Hemorrhage","enrollment":15},{"nctId":"NCT04836481","phase":"","title":"A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2021-01-01","conditions":"Traumatic Brain Injury","enrollment":10},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT00150709","phase":"PHASE3","title":"A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1998-01-26","conditions":"Epilepsy, Partial","enrollment":223},{"nctId":"NCT04559529","phase":"PHASE2","title":"Pharmacological Modulation of Hippocampal Activity in Psychosis 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-09-23","conditions":"Schizophrenia; Psychosis","enrollment":62},{"nctId":"NCT02550028","phase":"PHASE1, PHASE2","title":"Levetiracetam Treatment of Neonatal Seizures","status":"TERMINATED","sponsor":"Children's Hospital of Fudan University","startDate":"2015-09-01","conditions":"Neonatal Seizures","enrollment":60},{"nctId":"NCT06181383","phase":"","title":"Phenobarbital Versus Levetiracetam Neonatal Convulsion","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-30","conditions":"Neonatal Convulsion","enrollment":42},{"nctId":"NCT06138847","phase":"","title":"Does Levetiracetam and Carbamazepine Impact the Autonomic Activity of Children With Self-limiting Focal Epilepsy?","status":"UNKNOWN","sponsor":"İpek Dokurel","startDate":"2023-01-01","conditions":"Epilepsy; Syndrome, Seizures of Localized Onset","enrollment":119},{"nctId":"NCT05940935","phase":"","title":"The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations","status":"COMPLETED","sponsor":"Trakya University","startDate":"2023-05-22","conditions":"Metabolic Acidosis, Antiepileptic Drugs, Craniotomy","enrollment":35},{"nctId":"NCT06067412","phase":"NA","title":"Efficacy of Phenytoin vs Levetiracetam in Status Epilepticus at Institute of Child Health,Faisalabad","status":"COMPLETED","sponsor":"Shaheed Zulfiqar Ali Bhutto Medical University","startDate":"2022-08-01","conditions":"Status Epilepticus","enrollment":70},{"nctId":"NCT00152503","phase":"PHASE2","title":"Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2005-08-31","conditions":"Epilepsy, Partial","enrollment":59},{"nctId":"NCT05969054","phase":"PHASE4","title":"Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-05","conditions":"Alzheimer Disease 3, Epilepsy","enrollment":140},{"nctId":"NCT05860153","phase":"NA","title":"Intermittent Levetricetam in Treatment of Febrile Convulsions","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Febrile Convulsion","enrollment":100},{"nctId":"NCT03436433","phase":"PHASE2","title":"Seizure Prophylaxis in Patients With Glioma or Brain Metastasis","status":"TERMINATED","sponsor":"Duke University","startDate":"2019-01-31","conditions":"Glioma, Glioma of Brain, Brain Tumor","enrollment":4},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03129360","phase":"PHASE2","title":"Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-08-18","conditions":"Psychosis, Schizophrenia, Schizo Affective Disorder","enrollment":48},{"nctId":"NCT04117425","phase":"NA","title":"Pharmacokinetic and Placental Transfer of Levetiracetam","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-04-20","conditions":"Epilepsy in Pregnancy","enrollment":50},{"nctId":"NCT04926844","phase":"PHASE2","title":"Effectiveness of Combined Levetiracetam and Midazolam in Generalized Convulsive Status Epilepticus in Children","status":"COMPLETED","sponsor":"Sohag University","startDate":"2021-06-20","conditions":"Status Epilepticus, Generalized Convulsive Status Epilepticus, Status Epilepticus, Generalized","enrollment":144},{"nctId":"NCT05459597","phase":"","title":"Antiepileptic Drugs in Elderly Patients","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2021-01-01","conditions":"Seizure, Epileptic","enrollment":500},{"nctId":"NCT03636958","phase":"NA","title":"Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy","status":"WITHDRAWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2021-02-15","conditions":"Refractory Epilepsy","enrollment":""},{"nctId":"NCT00221988","phase":"NA","title":"Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-03","conditions":"Epilepsy","enrollment":40},{"nctId":"NCT02002819","phase":"PHASE2","title":"Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2014-10-16","conditions":"Alzheimer's Disease","enrollment":34},{"nctId":"NCT05330390","phase":"","title":"Study on the Population Pharmacokinetics of Levetiracetam in Epileptic Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"The Second Hospital of Shandong University","startDate":"2022-04-04","conditions":"Epilepsy, Diabetic Nephropathy","enrollment":50},{"nctId":"NCT05008354","phase":"PHASE4","title":"Effect of Pyridoxine on Behavioral Adverse Events of Levetiracetam","status":"COMPLETED","sponsor":"Nasim Tabrizi","startDate":"2020-10-01","conditions":"Epilepsy, Pyridoxine, Behavior Problem","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":38,"reaction":"IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME"},{"count":37,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":7,"reaction":"NEUROTOXICITY"},{"count":5,"reaction":"DELIRIUM"},{"count":4,"reaction":"CONVULSION"},{"count":3,"reaction":"HYPOXIA"},{"count":3,"reaction":"RENAL FAILURE"},{"count":3,"reaction":"TACHYCARDIA"},{"count":2,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":2,"reaction":"DECREASED APPETITE"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keppra","KEPPRA"],"phase":"marketed","status":"active","brandName":"Levetiracetam (Keppra)","genericName":"Levetiracetam (Keppra)","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release. Used for Partial-onset seizures (adjunctive therapy), Myoclonic seizures in patients with juvenile myoclonic epilepsy (adjunctive therapy), Primary generalized tonic-clonic seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}